Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

accelerated the rate of viral clearance, with comparable response at ANA598 doses of 200 mg bid and 400 mg bid.  ANA598 also showed an excellent safety profile in the study through the 12 weeks of dosing, with reported adverse events being typical for patients treated with interferon and ribavirin alone, although conclusions regarding safety cannot be made until results in more patients over longer duration are known.  Slides from the oral presentation are available on the Company's website at www.anadyspharma.com.On November 2, 2010, additional data from the ongoing Phase IIa trial were presented at AASLD showing that the addition of ANA598 to SOC conferred benefit in both the patients with the IL-28B genotypes most and less responsive to SOC in a poster titled, "IL28B Polymorphism and Kinetics of Antiviral Activity for ANA598 in Combination with Pegylated Interferon alpha 2A Plus Ribavirin in Treatment-Naïve Genotype-1 Chronic HCV Patients."  The poster is available on the Company's website at www.anadyspharma.com.


  • Phase IIa Study of ANA773 in HCV.  In October, Anadys announced that it plans to resume clinical investigation of ANA773 in hepatitis C patients.  ANA773 is an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway.  The Company intends to conduct a 28-day study of ANA773, in combination with ribavirin in the first cohorts and as triple therapy in combination with ribavirin and a direct-acting antiviral (DAA) in subsequent cohorts. Anadys intends to conduct this study in Europe and potentially other countries, and expects that up to approximately 75 patients will participate in the trial, inclusive of the DAA cohorts.Recent Operational Highlights

  • Closed Underwritten Public Offering of Common Stock.  In October, Anadys closed an underwritten public offering through the sale of c
    '/>"/>


  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
    (Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
    (Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
    Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
    ... pleased to announce first quarter 2012 revenues of $210,635, ... The increase in revenues was driven by surgeries at ... using the Kelyniam Custom Skull Implant made from PEEK ... quarter with the new management and a full sales ...
    ... SNDY) is pleased to announce that the Company has successfully ... $570,000.  As a result, the Company expects to achieve a ... financials, and show significant reduction of its liabilities for the ... issued Preferred Stock valued at $10 per share in order ...
    Cached Medicine Technology:Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012 2Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012 3Solos Endoscopy Reduces Liabilities by More than $570,000 2Solos Endoscopy Reduces Liabilities by More than $570,000 3
    (Date:7/12/2014)... York, NY (PRWEB) July 12, 2014 ... steady growth over the past five years, buoyed by ... agricultural sector's supply management system. “Eggs are a relatively ... result, per capita egg consumption generally grows in line ... Industry Analyst Will McKitterick. Furthermore, demand for new specialty ...
    (Date:7/12/2014)... 2014 The rise in the number ... new advanced network architectures to suit the upsurge. Virtualization ... with increasing cloud storage technologies. The data traffic has ... mobility devices. This has resulted in larger and more ... forces for the SDN market. , The North American ...
    (Date:7/12/2014)... The "North American ... Market by Angioplasty Balloon (Plain/Old, Cutting), ... IVC Filter (Retrievable), Endovascular Stent Graft ... studies the major market drivers, restraints, ... Canada. , Browse 108 market data ...
    (Date:7/12/2014)... The Security Analytics market is estimated to ... by 2019, at an expected CAGR of 9.7% for ... counter the increasing number of security breaches, continued line ... systems in organizations are enormous. Vendors in the security ... architecture to develop better and more secure systems. , ...
    (Date:7/12/2014)... Melbourne, Australia (PRWEB) July 12, 2014 ... past five years, despite rising competition from international and ... compound annual 2.9% over the five years through 2014-15. ... with consumers demanding more gaming services. Rises in discretionary ... have spent more money on non-essential items such as ...
    Breaking Medicine News(10 mins):Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4
    ... Failure by Sutter Medical Center Santa Rosa and Santa ... of county services fuels efforts to make ... SANTA ROSA, Calif., March 12 In the ... workers,at Santa Rosa Memorial Hospital -- already engaged in ...
    ... show whether an antidepressant is working , , TUESDAY, March ... biomarker for depression that could lead to a quick ... making headway against the disease. , "This may be ... co-author Mark Rasenick, director of the Interdisciplinary Neuroscience Program ...
    ... study in the,Journal of the American Medical Association ... Staphylococus aureus), a simple,skin or nasal swab, is ... for Methicillin-Resistant Staphylococcus aureus at,Hospital Admission and Nosocomial ... March 12, 2008)., The findings of the ...
    ... (NYSE:,WLP) announced today that senior management is scheduled to present at ... Healthcare Conference on March 13, 2008, ... Daylight Time (EDT);, -- Lehman Brothers ... March 19, 2008, at 10:15 a.m. EDT., All interested parties ...
    ... a good news, bad news situation. Some women who ... dont have cancer, they do have atypical hyperplasia -- ... someday. This happens to one-fourth of women undergoing breast ... risk. , In their quest to discover who is ...
    ... Zimmer Holdings, Inc.,(NYSE ZMH; SWX: ZMH), a leader in the ... upcoming investor,conferences:, -- March 18, 2008 -- Cowen,s ... Massachusetts, 8:00 a.m. Eastern Time -- March 19, 2008 ... Conference, Miami Beach, Florida, 8:30 a.m. Eastern Time, ...
    Cached Medicine News:Health News:Santa Rosa Healthcare Workers Seek Accountability From Catholic Hospital System 2Health News:Scientists Spot Biochemical Sign of Depression 2Health News:Scientists Spot Biochemical Sign of Depression 3Health News:JAMA Article Provides False Support for CDC's Do-Nothing Position on MRSA 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 2Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 3Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 4
    The new XMI catheter incorporates the best in catheter technology to ,provide exceptional handling characteristics comparable to todays balloon catheters and stent delivery systems....
    The new XVG catheter is our highest power thrombectomy catheter designed for accessing distal anatomy. Utilizing proprietary Cross-Stream water jet technology, the XVG catheter removes thrombus quick...
    Redel Connector 10 Pin...
    ... a non-fluoroscopic navigation system that tracks multiple ... Fred Wittkampf, Ph.D., and is being developed ... ,The LocaLisa system uses three ... around the heart to track catheters. Using ...
    Medicine Products: